Review of the advances on respiratory syncytial virus vaccine
LI Sun
SUN Dece
LI Xiaoyang
WEI Xinmiao
YANG Yang
QI Yuantong
YANG Hua
ZUO Qianfei
SONG Yanping
JIANG Mingmin
LAN Qing
MA Tao
Abstract：Respiratory syncytial virus(RSV)is a major cause of severe lower respiratory disease and can infect all populations,posing a significant health threat to infants and the elderly.After more than 60 years of research,there are only 2 RSV vaccines and 2 preventive monoclonal antibodies be licensed,but the use of the population is severely limited,expensive and difficult to large-scale popularization.RSV vaccine development faces a number of obstacles,such as the lack of animal models,avoidance of RSV immunity,and short duration of immunity.Since the failure of formalin inactivated RSV vaccine trials,RSV vaccine development has become more cautious and difficult.This article briefly reviews the research status of RSV vaccines,and introduces several representative vaccines currently under development,in order to facilitate researchers to review the latest progress and contribute to promoting vaccine research.
Keywords：Respiratory syncytial virusVaccine
Publication Date：2024-07-01
Online Publishing Date：2025-08-15(First online date of this platform, not the publication date of the document)
Pages：7( 609-615 )